Cryptome in deal with German biotech Xantos
27 May, 2005 by Graeme O'NeillMelbourne drug discovery biotech Cryptome Pharmaceuticals (ASX:CRP) has turned on its income tap after signing a collaboration agreement with Germany's Xantos Biomedicine to validate Xantos' lead anti-cancer molecule.
New biopharma Apollo readies for lift-off
27 May, 2005 by Graeme O'NeillSydney-based biopharma Apollo Life Sciences lodged its prospectus with the ASX yesterday to raise AUD$9.5 million from its IPO in June.
Bumper Aust cotton harvest said to validate GM technology
26 May, 2005 by Graeme O'NeillThe harvest of Australia's 2004/05 cotton crop, the first to involve full-scale production of new-generation, pest-resistant Bollgard 2 varieties, is nearing completion.
Pfizer P3 grant call nets 'massive' response
26 May, 2005 by Ruth BeranPfizer Australia has received a "massive" response to its first internal global call for submissions after it successfully won an AUD$10 million pharmaceutical partnerships program (P3) grant earlier this year.
Sirtex appoints new CEO
26 May, 2005 by Ruth BeranSydney biomedical company Sirtex Medical (ASX:SRX) has promoted Gilman Wong from chief operating officer to chief executive officer.
In brief: Psiron; Eqitx
25 May, 2005 by Staff WritersPsiron (ASX:PSX) has presented a research paper at the International Meeting on Molecular Biology of Picornaviruses showing anticancer activity of a new strain of its lead product (CVA21) against a wider range of colorectal cancer cells.
Microarrays provide clues to drug side effects
25 May, 2005 by Graeme O'NeillThe US Food and Drug Administration and Applied Biosystems researchers have recently collaborated on a comparative study of the genetic effects of the three commercialised glitazone drugs, using the company's microarray platform technology.
Bionomics acquires Iliad Chemicals
25 May, 2005 by Ruth BeranBionomics (ASX:BNO) has acquired unlisted Melbourne discovery company Iliad Chemicals for 40.9 million Bionomics shares - approximately AUD$6.1 million at current market prices.
Ventracor implants first European patient
24 May, 2005 by Renate KrelleSydney's Ventracor (ASX:VCR) has announced the first European implant of its VentrAssist device as part of its CE Mark Trial.
Genesis flush after ArboGen stoush settles
24 May, 2005 by Graeme O'NeillAuckland-based biotech Genesis Research (ASX/NZSX:GEN) has received a valuable boost to its bottom line after an out-of-court settlement of its long-running dispute with former US ally, Delaware-based forestry biotech company ArboGen.
Ambri back to the drawing board
24 May, 2005 by Ruth BeranMedical diagnostics company Ambri (ASX:ABI) is busy back at the drawing board developing a new chip biosensor after suspending the development of its SensiDX project.
Acrux signs dermatology products deal
23 May, 2005 by Ruth BeranSpecialty pharmaceutical company Acrux (ASX:ACR) has signed an agreement giving newly-formed San Francisco bay area company Napa Biosciences the rights to use Acrux's drug delivery technology in a number of dermatology products.
Ausbiotech appoints new CEO
19 May, 2005 by Staff WritersAustralian Red Cross Blood Service (ARCBS) executive Dr Anna Lavelle has been appointed as the new head of Australia's peak biotechnology industry organisation, AusBiotech.
Motivated by pharma woes, biotech blog makes debut
19 May, 2005 by Kevin DaviesA new life sciences blog, Biopeer, has made its debut at the 2005 Bio-IT World Conference and Expo.
In brief: Uscom, Antisense, Gropep, Bresagen
18 May, 2005 by Staff WritersSydney's Uscom (ASX:UCM) has responded to ASX's 'please explain' as to why its shares dropped from $1.40 on 10 May to a low of $1.00 on 17 May.
